460 related articles for article (PubMed ID: 19536068)
1. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.
Tzvetkov MV; Vormfelde SV; Balen D; Meineke I; Schmidt T; Sehrt D; Sabolić I; Koepsell H; Brockmöller J
Clin Pharmacol Ther; 2009 Sep; 86(3):299-306. PubMed ID: 19536068
[TBL] [Abstract][Full Text] [Related]
2. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.
Nies AT; Koepsell H; Winter S; Burk O; Klein K; Kerb R; Zanger UM; Keppler D; Schwab M; Schaeffeler E
Hepatology; 2009 Oct; 50(4):1227-40. PubMed ID: 19591196
[TBL] [Abstract][Full Text] [Related]
3. Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects.
Yoon H; Cho HY; Yoo HD; Kim SM; Lee YB
AAPS J; 2013 Apr; 15(2):571-80. PubMed ID: 23417334
[TBL] [Abstract][Full Text] [Related]
4. A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin.
Christensen MM; Pedersen RS; Stage TB; Brasch-Andersen C; Nielsen F; Damkier P; Beck-Nielsen H; Brøsen K
Pharmacogenet Genomics; 2013 Oct; 23(10):526-34. PubMed ID: 23873119
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of metformin.
Graham GG; Punt J; Arora M; Day RO; Doogue MP; Duong JK; Furlong TJ; Greenfield JR; Greenup LC; Kirkpatrick CM; Ray JE; Timmins P; Williams KM
Clin Pharmacokinet; 2011 Feb; 50(2):81-98. PubMed ID: 21241070
[TBL] [Abstract][Full Text] [Related]
6. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.
Tarasova L; Kalnina I; Geldnere K; Bumbure A; Ritenberga R; Nikitina-Zake L; Fridmanis D; Vaivade I; Pirags V; Klovins J
Pharmacogenet Genomics; 2012 Sep; 22(9):659-66. PubMed ID: 22735389
[TBL] [Abstract][Full Text] [Related]
7. The MATE1 rs2289669 polymorphism affects the renal clearance of metformin following ranitidine treatment.
Cho SK; Chung JY
Int J Clin Pharmacol Ther; 2016 Apr; 54(4):253-62. PubMed ID: 26784938
[TBL] [Abstract][Full Text] [Related]
8. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.
Shu Y; Brown C; Castro RA; Shi RJ; Lin ET; Owen RP; Sheardown SA; Yue L; Burchard EG; Brett CM; Giacomini KM
Clin Pharmacol Ther; 2008 Feb; 83(2):273-80. PubMed ID: 17609683
[TBL] [Abstract][Full Text] [Related]
9. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacogenet Genomics; 2010 Jan; 20(1):38-44. PubMed ID: 19898263
[TBL] [Abstract][Full Text] [Related]
10. Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure.
Komazawa H; Yamaguchi H; Hidaka K; Ogura J; Kobayashi M; Iseki K
J Pharm Sci; 2013 Mar; 102(3):1086-94. PubMed ID: 23280877
[TBL] [Abstract][Full Text] [Related]
11. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin.
Shikata E; Yamamoto R; Takane H; Shigemasa C; Ikeda T; Otsubo K; Ieiri I
J Hum Genet; 2007; 52(2):117-122. PubMed ID: 17111267
[TBL] [Abstract][Full Text] [Related]
12. Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations.
König J; Zolk O; Singer K; Hoffmann C; Fromm MF
Br J Pharmacol; 2011 Jun; 163(3):546-55. PubMed ID: 20883471
[TBL] [Abstract][Full Text] [Related]
13. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1.
Kimura N; Masuda S; Tanihara Y; Ueo H; Okuda M; Katsura T; Inui K
Drug Metab Pharmacokinet; 2005 Oct; 20(5):379-86. PubMed ID: 16272756
[TBL] [Abstract][Full Text] [Related]
14. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants.
Cho SK; Yoon JS; Lee MG; Lee DH; Lim LA; Park K; Park MS; Chung JY
Clin Pharmacol Ther; 2011 Mar; 89(3):416-21. PubMed ID: 21270793
[TBL] [Abstract][Full Text] [Related]
15. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
Shibata M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
Eur J Clin Pharmacol; 2020 Aug; 76(8):1135-1141. PubMed ID: 32472157
[TBL] [Abstract][Full Text] [Related]
16. Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes.
Song IS; Shin HJ; Shin JG
Xenobiotica; 2008 Sep; 38(9):1252-62. PubMed ID: 18728938
[TBL] [Abstract][Full Text] [Related]
17. Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
Higgins JW; Bedwell DW; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2012 Jun; 40(6):1170-7. PubMed ID: 22407892
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis.
Clarke JD; Dzierlenga AL; Nelson NR; Li H; Werts S; Goedken MJ; Cherrington NJ
Diabetes; 2015 Sep; 64(9):3305-13. PubMed ID: 26016715
[TBL] [Abstract][Full Text] [Related]
19. Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters.
Grün B; Kiessling MK; Burhenne J; Riedel KD; Weiss J; Rauch G; Haefeli WE; Czock D
Br J Clin Pharmacol; 2013 Nov; 76(5):787-96. PubMed ID: 23305245
[TBL] [Abstract][Full Text] [Related]
20. Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
Nishizawa K; Yoda N; Morokado F; Komori H; Nakanishi T; Tamai I
PLoS One; 2019; 14(4):e0214862. PubMed ID: 30951542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
